Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (82)

« Back to Publications

Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late.

Hammond SM. et al, (2010), PLoS One, 5

In vivo biodistribution and efficacy of peptide mediated delivery.

Järver P. et al, (2010), Trends Pharmacol Sci, 31, 528 - 535

Antisense oligonucleotide correction of splice error in cultured ISCU myopathy muscle cells

Sanaker PS. et al, (2010), NEUROMUSCULAR DISORDERS, 20, 676 - 676

Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO.

Yin H. et al, (2010), Mol Ther, 18, 1822 - 1829

Identification of a novel muscle targeting peptide in mdx mice.

Seow Y. et al, (2010), Peptides, 31, 1873 - 1877

Elusive copy number variation in the mouse genome.

Agam A. et al, (2010), PLoS One, 5

Cellular internalization kinetics of (luciferin-)cell-penetrating peptide conjugates.

Eiríksdóttir E. et al, (2010), Bioconjug Chem, 21, 1662 - 1672

Commercially available outbred mice for genome-wide association studies.

Yalcin B. et al, (2010), PLoS Genet, 6

A method for measuring allele-specific RNAi knock down in SCA7 patient lymphoblasts

Berkowitz D. et al, (2010), JOURNAL OF MEDICAL GENETICS, 47, S83 - S83

PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.

Hammond SM. and Wood MJ., (2010), Curr Opin Mol Ther, 12, 478 - 486

Benign hereditary chorea: clinical and neuroimaging features in an Italian family.

Salvatore E. et al, (2010), Mov Disord, 25, 1491 - 1496

Characterization of bioactive cell penetrating peptides from human cytochrome c: protein mimicry and the development of a novel apoptogenic agent.

Jones S. et al, (2010), Chem Biol, 17, 735 - 744

D-Serine metabolism in C6 glioma cells: Involvement of alanine-serine-cysteine transporter (ASCT2) and serine racemase (SRR) but not D-amino acid oxidase (DAO).

Sikka P. et al, (2010), J Neurosci Res, 88, 1829 - 1840

Erratum: Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: Prospects and risks (Gene Therapy (2010) 17 (592-605) DOI: 10.1038/gt.2010.2)

McMenamin MM. and Wood MJA., (2010), Gene Therapy, 17

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.

Lanzillo R. et al, (2010), Mult Scler, 16, 450 - 454

In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.

Wang Q. et al, (2010), J Gene Med, 12, 354 - 364

Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.

Yin H. et al, (2010), Mol Ther, 18, 819 - 827

Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: prospects and risks.

McMenamin MM. and Wood MJA., (2010), Gene Ther, 17, 448 - 458

RNA-targeted splice-correction therapy for neuromuscular disease.

Wood MJA. et al, (2010), Brain, 133, 957 - 972

Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge.

Wood MJA., (2010), Sci Transl Med, 2

Load More

1
2
3
4
5